May 4, 2010 (FinancialWire) — Biopharmaceutical firm Vivus, Inc. (NASDAQ: VVUS) has appointed Michael P. Miller to the position of senior vice president and chief commercial officer. The newly created position, reporting directly to CEO Leland Wilson, will be responsible for building and leading the commercial efforts for the company’s Qnexa drug, if approved, for commercial use.

Miller most recently served as vice president in the BioOncology Business Unit at Genentech, a wholly owned member of the Roche Group, where he presided over three marketing teams. He was also responsible for the pre-launch activities of multiple pipeline products and the U.S. commercial collaboration with OSI Pharmaceuticals.

Previously, Miller was senior vice president and chief commercial officer of Connectics. He also served as vice president at ALZA Corporation, a Johnson & Johnson Company, where he launched Ditropan XL and negotiated partnerships with companies including UCB Pharma, Abbott Laboratories and Bayer.

California-based Vivus is a biopharmaceutical company developing therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead investigational product candidate, Qnexa, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been submitted and accepted by the FDA, with an action date of October 28, 2010. 

Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea.

Streaming Research for all companies mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [clvloy]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.